Background: There is a great unmet clinical need for efficacious, tolerable, economical and orally administrated drugs for the treatment of inflammatory bowel disease (IBD). New therapeutic avenues have become possible including the development of medications that target specific genetic pathways found to be relevant in other immune mediated diseases.
| INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic and progressive immune mediated condition of the gastrointestinal (GI) tract influenced by both genetic and environmental factors. Often patients require lifelong medical therapy and others surgery depending on disease severity. A meta-analysis showed the 5 and 10 year risk for needing surgery for Crohn's disease (CD) and ulcerative colitis (UC) was 33.3%, 46.6%, 11.6% and 15.6% respectively. 1 Approximately 25% of CD patients will require additional intestinal surgery within 5 years of their first. 2 The risk of requiring surgery after diagnosis has decreased over the past six decades but remains a significant burden. 3 This has both financial implications and a negative impact on a patient's quality of life. 4 For a considerable duration, the mainstay of medical treatment for IBD has been the use of steroids for the induction of remission and immunomodulatory drugs such as azathioprine, mercaptopurine and methotrexate to maintain remission. 5 However, since 1997 when Targan et al. reported the first randomised controlled trial (RCT) to show the effectiveness of the anti-tumour necrosis factor (TNF) infliximab, there has been a paradigm shift in IBD management. This has led to the introduction of a number of anti-TNF and other biological agents such as adalimumab, certolizumab, golimumab, ustekinumab and vedolizumab. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] During the course of this disease, many patients are treated with various immunosuppressive medications either due to a lack of efficacy, loss of response or drug intolerance. 16 Up to a third of patients treated with anti-TNF therapy are primary nonresponders, whilst a significant proportion (10%-15% per year) lose response due to antibody formation (immunogenicity failure). 7, [17] [18] [19] These biological agents are also associated with significant adverse events, such as opportunistic infections and immune complications. 20, 21 Furthermore, these drugs have the added inconvenience of parenteral administration and associated heavy health care costs. 22 In a climate where hospital room capacity is limited, the use of novel oral medication could potentially increase capacity and reduce costs associated with drug infusions.
There remains a great unmet clinical need for new efficacious, tolerable, economical and orally administrated drugs. As our understanding of the major inflammatory pathways in IBD have evolved, multiple new therapeutic avenues have become possible. These include the development of new oral medications that target specific pathways found to be relevant in other immune mediated diseases.
These include inhibition of cytokine cell signalling, lymphocyte influx and mast cell activity, as well as promotion of the activity of inherent immunosuppressive pathways. 23 This review provides an overview of recent clinical trials for new generation oral targeted medications that may have a role in IBD management in the future.
| ME TH ODOLOGY
A broad electronic literature search was conducted using PubMed and Medline up to 1 March 2018 to identify the relevant studies.
The following keywords were used "IBD", "UC", "CD", "inflammatory bowel disease" "ulcerative colitis", "Crohn's disease", in combination with "phase", "study", "trial", and "oral". A manual search of the refer- 3 | POTE NTIAL NEW TREATMENTS:
Integrins comprise a family of a4b heterodimeric transmembrane receptors that are constitutively expressed on leucocyte surfaces and are activated by pro-inflammatory cytokines released by activated T cells. 24 The integrin family consists of at least 24 different forms representing the combination of 18 a subunits and 8 b subunits. The a-subunit determines integrin ligand specificity. The b-subunit connects to the cytoskeleton and affects multiple signalling pathways. 25 Inhibiting the interactions between adhesion molecules and lymphocyte integrins has already proved to be a successful therapeutic strategy for the management of IBD. 26 Vedolizumab is a recombinant humanized, anti-a4b7 integrin monoclonal antibody, which has shown efficacy for induction and remission in both UC and CD. 14,27 Natalizumab (Biogen Idec, Weston, MA, USA) an anti-a4 integrin antibody is also effective in IBD 28, 29 and etrolizumab (Roche, Basel, Switzerland) an anti-b7 integrin antibody was investigated in a phase II trial which showed this was more likely to lead to clinical remission than placebo in UC. 30 Phase III trials are currently being evaluated in IBD. [31] [32] [33] A more recent development is AJM300 (Ajinomoto Pharmaceuticals, Tokyo, Japan), an oral a4-integrin antagonist that acts by inhibiting the binding of lymphocyte integrins to adhesion molecules expressed on inflamed intestinal endothelium. 34 The gut specific a4b7 integrin is expressed on lymphocytes in the gut-associated lymphoid tissue, and interacts with mucosal addressin cell adhesion molecule 1 (MAdCAM-1), whilst the nongut-specific a4b1 integrin is expressed on most leucocytes and interacts with vascular cell adhesion molecule-1 (VCAM-1 Etrasimod (APD334; Arena Pharmaceuticals, San Diego, CA, USA) is a similar compound which selectively targets S1P1, S1P4
and S1P5 in in vitro assays thus also has the potential for immune cell modulation. 48 Etrasimod is currently been evaluated in a randomised, parallel phase II study in patients with UC. 49, 50 Another S1P receptor target that has completed a phase II study is amiselimod (MT-1303; Mitsubishi Tanabe Pharma Corporation, Osaka, Japan) in CD. 51 However, the development of amiselimod has recently been discontinued. A significant number of patients treated with 60 mg/day were in clinical remission when compared to placebo (31.6% vs 13.8%, P ≤ 0.05). Clinical response was significantly higher in the 80 mg/ day group when compared with placebo (67.3% vs 46.6%, P ≤ 0.05).
| Phosphodiesterase 4 inhibitor
In the 12 week follow-up, the 60 mg/day dose showed the most efficacy when compared with placebo. There were no new safety reports. 53 This phase II study is currently still active: patients will receive a further 40 weeks of treatment with either 60 mg/day or 80 mg/day of apremilast and be followed up to week 52. 54 
| Mitogen-activated protein kinase inhibitors
Mitogen-activated protein kinase (MAPK) superfamily plays an essential role in eukaryotic cell regulation to produce pro-inflammatory cytokines. P38a, JNKs and ERK1/2 have been shown to be significantly activated in the inflamed colonic mucosa of IBD patients.
55
RDP58 (SangStat Medical Corporation, Fremont, CA, USA), also known as delmitide acetate, is a drug that disrupts cell signalling which is responsible for activating p38 MAPK, JNK and I kappa kinase (IKK). 56 Travis et al first evaluated the efficacy, safety and tolerability of RDP58 in a phase II trial. 57 Data for two studies were reported for patients with mild-to-moderate UC (Simple Colitis Activity Index [SCCAI]) score 4-9 and active disease at sigmoidoscopy (Baron Score≥ 1) within this trial. In the first study, 34
patients were randomised (2:1) to RDP58 100 mg or placebo. In the second study, 93 patients were randomised (1:1:1) to receive RDP58 200 mg, RDP 300 mg or placebo.
No statistical difference was observed in the primary and secondary endpoints between RDP58 100 mg and placebo. In the second study, treatment success was higher with increasing doses: 71%
and 72% for the 200 mg and the 300 mg dose respectively when compared to 43% for placebo (P = 0.016). Adverse events were similar between RDP58 300 mg and placebo. 57 No further clinical trials evaluating RDP58 in UC are planned.
| Modified release phosphatidycholine
UC patients have been found to have a low intrinsic phosphatidylcholine content that reduces intestinal mucus barrier function, making it more susceptible to inflammation and ulcers. 58, 59 An improved, modified release phosphatidylcholine (LT02; Dr. Falk Pharma GmbH, Freiburg, Germany) and the first oral therapy targeting stabilisation of gut barrier was evaluated in a double-blinded, randomised, placebo-con- It also exhibits effects on regulatory T cells by promoting their differentiation. 79 A study in experimental autoimmune encephalomyelitis (an animal model of MS) has found that quinolone-3-carboxamides inhibited the interaction of S100A9 with 2 receptors, toll-like receptor 4 and receptor of advanced glycation end products, thereby preventing the downstream release of inflammatory cytokines, including tumour necrosis factor a (TNFa) and interleukin (IL)- 
| Antisense oligonucleotide SMAD7 inhibitor
Reduced tissue growth factor-b receptor type I (TGF-b1) cytokine activity due to overexpression of SMAD7 is seen in individuals with IBD. 86, 87 Mongersen (GED-0301; Celgene) is a new class of drug 86 which acts to reinstate the TGF-b1 immunosuppressive pathway. 88 Mongersen's efficacy and safety was evaluated in a multicentre, randomised, double-blind, placebo-controlled phase II trial involving 166 patients with moderate-to-severe CD (Crohn's Disease Activity Index 220-400). Participants were randomised to receive placebo or daily mongersen for 14 days. Clinical response was significantly higher in the 160 mg and 40 mg/day groups when compared to placebo (65% and 55% vs 10%, P < 0.001. 89 A post-hoc analysis of this trial showed neither an elevated CRP nor duration of disease impacted on efficacy. No association was seen between baseline CDAI and remission rates but the 40 mg dose showed the lowest remission rates with CDAI ≥260.
90
However, a significant limitation of the Monteleone et al study was that the inclusion criteria were based on CDAI score and with no objective endoscopic measure of disease activity. At baseline, 39% of participants had a normal CRP 91 implying low disease activity in the exposed population, so patients were not reflective of the usual moderate-to-severe patients. Moreover the primary endpoint was clinical remission only as measured through CDAI and this was only measured at 28 days. As such, no data are available on longterm clinical remission, endoscopic remission or safety.
In a recent noteworthy turn of events, Celgene has recently terminated their phase III REVOLVE and SUSTAIN clinical trials of mongersen following recommendation from the external Data Monitoring
Committee. This decision was based upon the lack of emerging benefit but not safety findings during their recent review of interim unblinded data. The planned Phase III DEFINE study in Crohn's will also not be initiated. However, a phase II trial in UC has recently completed recruitment. 92 Celgene is waiting to review the full dataset from this trial for UC to determine the next steps.
| POTE NTIAL NEW TREATMENTS:
CROHN' S DISEASE AND ULCERATIVE COLITIS 
| Janus kinase inhibitors

| Tofacitinib
Tofacitinib (CP-690,550; Pfizer, New York City, NY, USA) is a JAK 1 and 3 inhibitor that has been studied in autoimmune conditions, including rheumatoid arthritis and psoriasis with a good overall efficacy and an acceptable safety profile.
97-99
The use of tofacitinib in UC was evaluated in a multi-centre, double-blind, placebo-controlled, dose-ranging phase II study, including 194 adults with moderate-to-severe active UC (Mayo score ≥6
and endoscopic subscore ≥2) who had failed conventional therapy. 100 Stable doses of mesalazine (mesalamine) or prednisolone at a maximum of 30 mg were permitted during the trial period. Patients were randomised to tofacitinib 0.5, 3, 10, or 15 mg or placebo twice daily for 8 weeks. The primary efficacy endpoint was a clinical response, defined as an absolute decrease in Mayo score of ≥3 points and relative decrease ≥30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of 0 or 1. Of the secondary endpoints, clinical remission was defined as Mayo score ≤2 with no individual subscore >1 at week 8, endoscopic response was defined as a decrease from baseline in the subscore ≥1 at week 8 and endoscopic remission was defined as endoscopy subscore of 0 at week 8. The only statistical significant clinical response was with the 15 mg twice a day dose when compared to placebo (78% vs 42%, P < 0.001). Clinical remission was 13%, 33%, 48% and 41% at 0.5 mg (P = 0.76), 3 mg P = 0.01), 10 mg (P < 0.001) and 15 mg (P < 0.001), respectively when compared with 10% for placebo. Tofacitinib was well tolerated and reasonably effective in moderate-to-severe UC. 100 Tofacitinib is also associated with dose-dependent improvement in health related quality of life measures. 101 Faecal calprotectin showed a moderate correlation with clinical and endoscopic outcomes in patients receiving tofacitinib. A cut-off value of 150 mg/kg showed a fair to good accuracy in classifying these outcomes. the OCTAVE 2 trial this was 16.6% vs 3.6% (P < 0.001). In the OCTAVE 1 trial, the 10 mg group mucosal healing rate was 31.3% compared to placebo 15.6% (P < 0.001). In the OCTAVE 2 trial, this was 28.4% vs 11.6% (P < 0.001).
Patients who achieved a clinical response (reduction total Mayo score ≥3 points, rectal bleeding score ≥1 or absolute rectal bleeding subscore of 0 or 1) in the OCTAVE 1 and 2 were eligible to participate in the third OCTAVE Sustain trial. Patients were randomised
(1:1:1) to receive 5 mg, 10 mg or placebo twice a day for 52 weeks.
The primary endpoint was remission at 52 weeks. Secondary endpoints were mucosal healing at 52 weeks and sustained steroid free remission (both at 24 and 52 weeks). In this trial clinical remission at 52 weeks were 34.3% in 5 mg group, 40.6% in the 10 mg group compared with 11.1% in the placebo (P < 0.001 for both comparisons). Mucosal healing occurred in significantly more patients at 52 weeks. In the 5 mg, 10 mg and placebo this was 37.4%, 45.7% and 13.1% (P < 0.001) respectively. Sustained steroid free remission was 34.4%, 47.3% and 5.1% (P < 0.001) in the 5 mg, 10 mg and placebo group respectively. These results demonstrate that tofacitnib is more effective as an induction and maintenance agent than placebo. 103 The 3-year interim efficacy and safety data from the OCTAVE 1, 2 and OCTAVE Sustain studies open label long-term extension study reported a similar safety profile to those observed with rheumatoid arthritis patients and a sustained efficacy with 5 and 10 mg twice a day dose. 104 Currently, 1 phase I trial 105 There was no significant difference in the primary and secondary endpoints. It is unclear whether these findings are due to the high placebo response rate or difference in the immunopathology CD and UC. 107 Pan es et al reported a recently conducted phase IIb trial in which CD patients were randomised to 5 mg (n = 86), 10 mg twice (n = 86) or placebo (n = 91) twice a day for 8 weeks. There was no significant difference in remission rates reported despite the longer treatment duration. The clinical response was slightly significantly higher as was CRP reduction in the tofacitinib group when compared to placebo. There was no change in faecal calprotectin levels.
108
Pan es et al later reported on two randomised, double-blind, placebocontrolled, multicentre phase IIb studies of 180 patients with moderate-to-severe CD. Clinical remission was not significantly different to placebo although there were minor treatment benefits seen in change in biomarkers (secondary endpoints). 109 A number of factors may have contributed to the high response rate seen in placebo patients.
Endoscopy was not centrally read and the severity and extent of ulcers was not defined despite been part of the inclusion criteria.
There was also no baseline threshold for objective markers of disease activity. Variation in endoscopic ulcers and inflammatory markers at baseline may have influence the treatment effect of drugs.
109,110
The most commonly reported adverse events were influenza and nasopharyngitis. Neutropenia has also been reported as well as serious infections such as abscess and pneumonia. There was also a dose-dependent increase in low-density lipoprotein and high-density lipoprotein cholesterol which is not completely understood. | 1615 41% in placebo (P = 0.453). Clinical remission was 47% compared to 23% in placebo (P = 0.077). The safety profile was satisfactory and clinical remission was induced in the filgotinib group. Response rate was almost 2-fold higher in patients na€ ıve to anti-TNFs compared to those exposed to at least one. The data suggest that filgotinib could be effective in both anti-TNF na€ ıve and exposed. 111 A recent post hoc analysis of this phase II study showed that clinical remission is still seen in CD regardless of disease location and duration. 112 Currently phase III trials are underway in CD and UC. 24 mg twice a day and 24 mg once a day compared to placebo (8% P ≤ 0.05, 22% P ≤ 0.001, 14% P ≤ 0.01 and 0% respectively). This study demonstrated both clinical and endoscopic benefit with 6 mg doses and above. 117, 118 Upadacitinib use also results in a significant and sustainable reduction in markers of inflammation. 119 Upadacitinib is also currently being evaluated in phase II trials in UC. 120 
| Further development
A number of JAK inhibitors are currently in the development phase. A Phase IIb multi-centre randomised, double-blind, placebo-controlled, parallel group, dose-response trial evaluating the safety and efficacy of peficitinib (ASP015K; Astellas Pharma, Tokyo, Japan), a nonselec- • Placebo 17%
• 10 mg/day 37% (P = 0.04)
• 40 mg/day 58% (P < 0.001)
• 160 mg/day 72% (P < 0.001)
• Placebo 10%
• 10 mg/day 12% • 40 mg/day 55% • 160 mg/day 65% (P < 0.001)
Significant dose-related treatment benefit that is sustained, with safety profile similar to placebo. | 1617
Other weakness with a number of the CD trials is that they do not assess mucosal healing at endoscopy which is a desirable treatment goal that leads to increased rates of clinical remission, reduced hospitalisation and surgery rates. 127 Other weaknesses include low CRP at inclusion, no centrally read endoscopy, short follow-up period and a lack of forced steroid tapering dosage. Rectifying these weaknesses is likely to give a true reflection of the difference between the trial agents and placebo, therefore, potentially enabling better design and success at phase III.
Novel However, long-term infection and malignancy rates also need to be better determined in large prospective studies in addition to side effects, hospital admission rates and other significant costs. There is a growing need for long phase IV studies for these drugs in development and the use of registries like TREAT and PIANO to assess the long-term safety of these drugs. Potentially, the development of more targeted therapies may also mean that complications can be avoided in susceptible individuals compared to the current blanket approach to treatment.
At present, the majority of IBD patients respond to some form of current therapy but the loss of response is a problem. Although population-based studies are suggesting a decrease in surgical rates for both CD and UC, 3, 128 better and more targeted therapies are needed to sustain this paradigm shift world-wide. There is presently no headto-head comparison between presently licenced therapies and future targeted therapies to allow a better understanding of when these targeted therapies should be introduced in present treatment algorithms.
Moreover, there are no clear predictive biomarkers to identify the subgroups of IBD patients that will respond to these new targeted therapies. If these agents are successful, then this will lead to an exciting new era of personalised and precise therapy in IBD, as is already the case in other areas of medicine.
